

Mount Sinai
MEDICAL CENTER
Comprehensive Cancer Center



2008
ANNUAL REPORT
Reflecting 2007 Data

OUTSTANDING ACHIEVEMENT AWARD
COMMISSION ON CANCER
APPROVED PROGRAM

Mount Sinai

M E D I C A L C E N T E R

Although a cure for cancer has yet to be discovered, our understanding of the disease is advancing at a rapid rate. Today, there are many more options for people diagnosed with cancer than there were 20, 10 or even just five years ago. In our Comprehensive Cancer Center, we are working to develop new therapies and treatments and to make them available to as many patients as possible.

In fact, Mount Sinai provides the framework for cancer research and collaboration among several local hospitals. We are the only Florida hospital to earn a multi-million dollar grant from the National Cancer Institute for an adult Community Clinical Oncology Program. This funding allows us to direct cancer studies, here, and at other hospital sites, participate in as many as 60 clinical trials, and offer to patients access to drugs and therapies long before they are widely available.

This work is helping to revolutionize patient care. For example, a study of a drug called Herceptin found that when it was combined with chemotherapy for early-stage breast cancer, researchers were able to reduce recurrence rates by a remarkable 52%.

We offer innovative therapies ranging from chemoembolization to advanced radiation treatment options and minimally invasive oncologic surgical techniques. Mount Sinai at Aventura offers a second location for the convenience of patients. Our 12,000 square foot location is comprised of medical and radiation oncology services, as well as physician offices and imaging services. In addition to these services, oncology supportive care services are also available to our patients.

The physicians and clinical staff of the Cancer Program work closely with each patient to ensure a whole-person, compassionate approach to care. The program conducts weekly multi-disciplinary conferences. During these conferences, physicians in oncology subspecialties come together to discuss the best treatment options for patients.

The Cancer Committee and its support staff are proud to bring together this Annual Report 2008.



Rogerio Lilenbaum, M.D.
Chairman, Cancer Committee



Steven Sonenreich
President and CEO

Mount Sinai Campus
4300 Alton Road
Miami Beach, FL 33140
Phone: 305-674-2121
www.msmc.com

Mount Sinai Aventura
2845 Aventura Boulevard
Aventura, FL 33180
Phone: 305-932-2099

2007 SITE DISTRIBUTION

PRIMARY SITE	Total	Class		SEX		SEX		AJCC						
	All	A	N/A	M	F	M	F	STAGE	I	II	III	IV	UNK	N/A
				all cases		analytic only								
ALL SITES	2038	1500	538	1037	1001	724	776	99	371	354	170	204	101	201
ORAL CAVITY	36	27	9	20	16	16	11	1	5	2	2	13	1	3
LIP	2	1	1	2	0	1	0	0	1	0	0	0	0	0
TONGUE	7	5	2	3	4	2	3	0	0	0	2	3	0	0
OROPHARYNX	1	1	0	1	0	1	0	0	0	0	0	0	1	0
HYPOPHARYNX	1	1	0	1	0	1	0	0	0	0	0	1	0	0
OTHER	25	19	6	13	12	11	8	1	4	2	0	9	0	3
DIGESTIVE SYSTEM	353	275	78	194	159	146	129	20	58	50	49	58	29	11
ESOPHAGUS	19	13	6	13	6	8	5	0	2	3	0	5	3	0
STOMACH	37	28	9	22	15	17	11	0	8	3	1	12	4	0
COLON	112	78	34	59	53	39	39	7	23	12	14	14	8	0
RECTUM	53	44	9	35	18	29	15	4	12	11	12	2	2	1
ANUS/ANAL CANAL	26	25	1	12	14	12	13	7	6	3	5	1	3	0
LIVER	25	20	5	16	9	11	9	0	3	3	8	4	2	0
PANCREAS	53	43	10	23	30	19	24	2	2	10	8	15	4	2
OTHER	28	24	4	14	14	11	13	0	2	5	1	5	3	8
RESPIRATORY SYSTEM	208	146	62	128	80	87	59	0	42	13	27	50	8	6
NASAL/SINUS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LARYNX	8	3	5	7	1	3	0	0	2	0	0	0	1	0
LUNG/BRONCHUS	194	138	56	120	74	83	55	0	39	13	25	49	7	5
OTHER	6	5	1	1	5	1	4	0	1	0	2	1	0	1
BLOOD & BONE MARROW	113	74	39	66	47	42	32	0	0	0	0	0	0	74
LEUKEMIA	51	31	20	29	22	16	15	0	0	0	0	0	0	31
MULTIPLE MYELOMA	30	17	13	19	11	10	7	0	0	0	0	0	0	17
OTHER	32	26	6	18	14	16	10	0	0	0	0	0	0	26
BONE	1	0	1	1	0	0	0	0	0	0	0	0	0	0
CONNECT/SOFT TISSUE	5	4	1	4	1	4	0	0	2	2	0	0	0	0

2007 SITE DISTRIBUTION

PRIMARY SITE	Total	Class		SEX		SEX		AJCC STAGE						
SKIN	153	91	62	87	66	47	44	23	31	9	13	3	1	11
MELANOMA	132	83	49	70	62	42	41	23	30	9	13	3	1	4
OTHER	21	8	13	17	4	5	3	0	1	0	0	0	0	7
BREAST	373	299	74	5	368	3	296	39	117	72	37	14	20	0
FEMALE GENITAL	82	69	13	0	82	0	69	2	31	2	13	9	7	5
CERVIX UTERI	11	10	1	0	11	0	10	0	7	0	1	0	2	0
CORPUS UTERI	39	36	3	0	39	0	36	0	18	0	6	3	5	4
OVARY	24	15	9	0	24	0	15	0	3	0	6	6	0	0
VULVA	4	4	0	0	4	0	4	2	0	2	0	0	0	0
OTHER	4	4	0	0	4	0	4	0	3	0	0	0	0	1
MALE GENITAL	295	210	85	295	0	210	0	0	3	180	8	12	5	2
PROSTATE	288	203	85	288	0	203	0	0	0	180	7	11	5	0
TESTIS	4	4	0	4	0	4	0	0	3	0	1	0	0	0
OTHER	3	3	0	3	0	3	0	0	0	0	0	1	0	2
URINARY SYSTEM	149	107	42	102	47	70	37	14	29	13	13	13	23	2
BLADDER	73	43	30	54	19	30	13	13	10	8	3	4	5	0
KIDNEY/RENAL	71	59	12	43	28	35	24	1	19	4	10	9	16	0
OTHER	5	5	0	5	0	5	0	0	0	1	0	0	2	2
BRAIN & CNS	55	36	19	21	34	19	17	0	0	0	0	0	0	36
BRAIN (BENIGN)	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BRAIN (MALIGNANT)	14	9	5	8	6	8	1	0	0	0	0	0	0	9
OTHER	41	27	14	13	28	11	16	0	0	0	0	0	0	27
ENDOCRINE	88	77	11	33	55	28	49	0	30	4	0	6	3	34
THYROID	48	43	5	14	34	11	32	0	30	4	0	6	3	0
OTHER	40	34	6	19	21	17	17	0	0	0	0	0	0	34
LYMPHATIC SYSTEM	102	66	36	69	33	43	23	0	22	7	8	25	4	0
HODGKIN'S DISEASE	13	10	3	10	3	7	3	0	2	3	1	3	1	0
NON-HODGKIN'S	89	56	33	59	30	36	20	0	20	4	7	22	3	0
UNKNOWN PRIMARY	20	16	4	10	10	8	8	0	0	0	0	0	0	16
OTHER/ILL-DEFINED	5	3	2	2	3	1	2	0	1	0	0	1	0	1

Number of cases excluded: 38

This report excludes historical cancer cases which were not treated at this facility.


MOUNT SINAI COMPREHENSIVE CANCER CENTER - MIAMI BEACH




MOUNT SINAI COMPREHENSIVE CANCER CENTER - AVENTURA



2007 TOP 5 SITES



2007 TOP 5 SITES AT CONFERENCES





2008 ACCOMPLISHMENTS

Diagnostic Imaging Center:

- 16-slice CT Scanner
- 64-slice CT Scanner
- 3-Tesla MRI

Breast Center:

- Application accepted for National Accreditation Program for Breast Centers (NAPBC)
- Initiated Patient Navigator
- New Stereotactic Biopsy Equipment

MSCCC/MSMC:

- Dr. Juan Paramo appointed as Commission on Cancer Florida State Chair
- Recruited a new medical oncologist, colo-rectal surgeon & urologic oncology surgeon
- Added a Patient Navigator to the Tumor Clinic
- Added TOPEX SRT 100 superficial x-ray therapy system to treat skin cancer
- Upgraded ARIA (record and verifying system) software
- Upgraded Cone Beam CT/Trilogy: clearer images available on physician workstations
- Instituted Tobacco Treatment Program
- Provided Financial Counseling for all patients
- Updated to a new Hematology Instrument – LH750
- Affiliated with Columbia University, Division of Urology

FOCUS ON:

Diagnostic Imaging Services

The expertise and technology of a teaching hospital with the convenience of an outpatient facility at Mount Sinai Medical Center, you can have it all under one roof.

We boast state of the art imaging equipment, including a new 64-slice CT scanner and a 3T MRI. Because an accurate diagnosis is the first step to proper treatment, Mount Sinai provides board-certified radiologists specially trained in a wide variety of subspecialties, including body imaging, neuroradiology, interventional radiology, musculoskeletal and cardiac imaging. It's a distinction that sets Mount Sinai apart and ensures patients get the best possible care. In addition, prompt results are available within 24 hours for the benefit of referring physicians and their patients.

State Of The Art Diagnostic Services

- | | |
|----------------------------|---------------------------------------|
| ◦ 16 & 64 Multi-Slice CT | ◦ PET-CT Scan |
| ◦ Interventional Radiology | ◦ Bone Densitometry |
| ◦ High Field MRI | ◦ Fluoroscopy |
| ◦ Nuclear Medicine | ◦ General X-ray |
| ◦ Ultrasound/Vascular Lab | ◦ Digital Mammography/ Breast Imaging |

TREATMENT AND SURVIVAL OF NON-HODGKIN LYMPHOMA PATIENTS OVER THE AGE OF 80

AUTHOR BLOCK: F. O. Nascimento, H. P. Soares, A. Ruiz, G. B. Weinberg, M. Cusnir, Mount Sinai Medical Center, Miami Beach, FL

ABSTRACT:

Background: The incidence of Non-Hodgkin Lymphoma (NHL) has been increasing by 1-2% annually; the rise is most dramatic in patients over 80, in whom the rate rose 500% in the last 2 decades. Elderly are usually excluded from clinical trials, and often from treatment; thus, optimal treatment for elderly patients is unknown. The objective of this study was to review the characteristics, management and outcomes of NHL patients older than 80 years at diagnosis.

METHODS:

The records of all patients over age 80 diagnosed with NHL from 2000 to 2005 were reviewed. A total of 107 patients were found and categorized as per the WHO classification. For statistical analysis, the patients were divided into subgroups: (I) type of tumor (a. aggressive, b. indolent), (II) international prognostic index (IPI) (1-2: low, 3-5: high), and (III) chemotherapy protocol (a. standard, b. non-anthracycline, c. no treatment). Overall survival rates were compared among subgroups of patients.

RESULTS:


Thirty patients (28%) received standard chemotherapy (CHOP or CHOP-Rituximab). Forty-five (42%) received non-anthracycline chemotherapy and 32 (30%) were not treated. Overall 1-year and 3-year survival rates were $61.1 \pm 11.8\%$ and $22.3 \pm 8.4\%$. The median survival time was 21 ± 6 months. The indolent subgroup had better 1 and 3-year survival than the aggressive subgroup (70.5% and 28% versus 47.1% and 9.1% respectively, $p=0.01$). Similar results were seen in patients with low grade IPI when compared with high grade IPI (62.2% and 43% versus 41% and 8.1% respectively, $p=0.002$).

The CHOP subgroup was compared with the non-anthracycline and “no treatment” subgroups in the different subtypes. In the aggressive subgroup, patients treated with CHOP had significantly longer 1-year and 3-year survival rates than those treated with non-anthracycline (76% and 42% versus 35.8% and 17% respectively, $p=0.014$) or those receiving no treatment (28.5% and zero, $p=0.001$).

CONCLUSIONS:


Very elderly patients with aggressive NHL (large B-cell) have significantly better survival rates at 1 and 3 years when treated with CHOP or CHOP-R. Age alone should not be a contraindication to treatment. Chemotherapy, however, did not affect outcome in patients with indolent NHL.

LYMPHOMA >80Y: RX TYPE




LYMPHOMA ALL AGE BY SEX

Age Range	Male	Female
10 - 19	4	6
20 - 29	14	9
30 - 39	27	16
40 - 49	54	17
50 - 59	51	26
60 - 69	35	26
70 - 79	55	68
80 - 89	44	45
90 - 99	4	16
100 - 109	0	1
TOTALS	288	230




LYMPHOMA: 2000-2006 DECADE AT DIAGNOSIS

(NATIONAL CANCER DATA BASE)



LYMPHOMA: 2000-06 STAGE AT DIAGNOSIS

(NATIONAL CANCER DATA BASE)



2007 SITE COMPARISON (5 MOST PREVALENT CANCER SITES)



*Source: American Cancer Society "Cancer Facts & Figures 2007"

RESEARCH

Research is a vital component of the mission of Mount Sinai Medical Center and the Comprehensive Cancer Center. Mount Sinai's Community Clinical Oncology Program (MSCCOP) has entered its 22nd year of participation in the prestigious national CCOP initiative, which brings new research, resources and hope to patients and physicians fighting cancer in our community. Mount Sinai is home to the only CCOP in the state of Florida conducting progressive research of cancer in adults.

In its 22 years of research, the Mount Sinai CCOP has been involved in numerous studies that have broken ground for new treatments for cancer. Mount Sinai physicians choose to participate in the cancer trials they believe are most promising. Annually, MSCCOP accrues over 150 patients to treatment and prevention studies and is a leader in minority accrual with 21% Hispanic patients and 15% African American patients. With more than 45 active clinical trials, the Comprehensive Cancer Center had approximately 7% of patients enrolled in clinical trials which exceeded the standard set forth by the Commission on Cancer.

Our research studies are directed by a group of senior physicians, led by the Director of Cancer Research, Rogerio Lilenbaum, M.D., and a team of support personnel. The group manages the clinical research projects for 45 physicians, offering a wide variety of research opportunities sponsored by the National Cancer Institute and pharmaceutical companies. The new research initiatives in 2008 included the activation of 16 treatment clinical research trials and 1 prevention trial. These new initiatives increased the number of active clinical trials at Mount Sinai Medical Center to 46 and increased the number of patients currently participating in clinical research to 335.

2008 RESEARCH HIGHLIGHTS

National Institutes of Health Community Clinical Oncology Program \$3 million Grant: The grant enables Mount Sinai to provide patients access to cutting-edge cancer treatments and novel cancer prevention therapies years before they are widely available.

MSCCOP Website Expansion : The website (www.msccop.com) was developed several years ago, primarily for the purpose of facilitating communication with community institutions and to provide general information on MSCCOP. The website currently contains comprehensive information about the program, available clinical research trials, research base affiliations and participating physicians.

Fifth Annual Lung Cancer Symposium: This symposium is an important element of MSCCOP's mission to provide ongoing education of investigators and community physicians related to advancements in clinical oncology. The fifth annual Winter Lung Cancer Conference was held March 14-16, 2008. This Continuing Medical Education conference is organized and chaired by Rogerio Lilenbaum, M.D. National experts from across the United States participated in the symposium.

2007-2008 CANCER COMMITTEE MEMBERS

Mount Sinai Medical Center
Comprehensive Cancer Center



Sitting, from left to right:

Robert Goldszer, MD, MBA

Sr. Vice President

Chief Medical Officer, MSMC

Janet Williams, ARNP, MSN, OCN

Nurse Practitioner

Ana L. Ruiz, CTR

Manager, Cancer Registry

Juan Paramo, MD

Cancer Liaison Physician

Leigh Kiger, RN

Administrator, CCOP

Elisa Krill-Jackson, MD

Co-Chair, Cancer Committee

Standing, from left to right:

Rogério Lilenbaum, MD

Chair, Cancer Committee

Laura M. Pollett

American Cancer Society

Robert Poppiti, MD

Chairman, Pathology & Lab Medicine

Deborah Belcher

Manager, Diagnostic Imaging

Barry Shipman, DMD

Dentistry & Prostadontics

Florence Buenconsejo, ARNP, MSN, OCN

Director, Clinical Operations, Cancer Center

Patrick Reynolds, MD

Palliative Care Services

Guerna Blot, RN

Nurse Manager, IP Oncology Unit: 5-Main

Craig Covington

Executive Director, Cancer Center

Gail Brown, LCSW

Oncology Supportive Care Services

Leonard Toonkel, MD

Chairman, Radiation Oncology

Marsha Hood, RHIA

Director HIM, Compliance

Not present:

Stuart Kaplan, MD

Section Chief, Breast Imaging

Thomas Mesko, MD

Chief, Surgical Oncology

Jeffrey Neitlich, MD

Chairman, Radiology

Daniel Nixon, MD

Emeritus

Berta Rios, Ph.D

American Cancer Society

Sandy Sotnick, MS, RD

Supervisor, Nutrition Services

THE BEST CANCER CARE



Mount Sinai Medical Center is proud to announce we are the only teaching hospital in Florida to win the Commission on Cancer's Outstanding Achievement for a second consecutive time.

**You deserve the best cancer care.
Choose Mount Sinai to be sure
you're getting it.**

For more information or a physician referral,
please call 305-674-CARE(2273).

Mount Sinai
MEDICAL CENTER
Comprehensive Cancer Center

4306 Alton Road, Miami Beach, Florida 33140 305-674-9100